CMA Defends £100M Fine Over Advanz Thyroid Drug Pricing
By Joanne Faulkner ( September 28, 2022, 7:43 PM BST) -- The U.K.'s competition watchdog told a tribunal Wednesday that the prices charged by pharmaceutical company Advanz for its thyroid tablets were excessive and unfair as it began its defense of a £100 million ($107 million) fine....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.